Peptide LibraryCerebrolysin dosage in published studies and labels
These are the doses used for Cerebrolysin in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Cerebrolysin has no approved dosage in the United States. In the large stroke trials it was dosed by volume: 30 mL once daily by intravenous infusion for 10 days in the CASTA trial (n=1,070), and 30 mL once daily for 21 days alongside rehabilitation in the CARS trial. CASTA did not meet its primary endpoint; CARS reported better arm function at day 90.
| Human dosing established | Yes |
|---|---|
| Route | Intravenous infusion (the route in the large trials) |
| Frequency | Once daily |
| Duration studied | 10–21 days in the stroke trials |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| CASTA — acute ischaemic stroke in Asia (2012)Clinical trial · Double-blind randomised placebo-controlled trial | Adults with acute ischaemic hemispheric stroke, treated within 12 hours of onset (n=1,070) | 30 mL a day, with aspirin 100 mg a day | Intravenous infusion | Once daily | 10 days | No significant difference on the combined primary endpoint (modified Rankin Scale, Barthel Index, NIHSS) | Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012. |
| CARS — recovery after stroke (2016)Clinical trial · Double-blind randomised placebo-controlled multicentre trial | Adults in early rehabilitation after stroke, treated from 24–72 hours after onset | 30 mL a day | Not stated in the indexed abstract | Once daily | 21 days | Action Research Arm Test score at day 90 favoured cerebrolysin; the authors called the study exploratory | Cerebrolysin and Recovery After Stroke (CARS): A Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial. Stroke. 2016. |
Where sources disagree
- Cerebrolysin is a mixture of low-molecular-weight peptides and amino acids prepared from pig brain, not a single peptide, so it is dosed in millilitres rather than milligrams.
- This profile's general route lists intramuscular use, but the large stroke trials gave 30 mL by intravenous infusion. Trial volumes do not transfer to intramuscular injection.
- Results are mixed: the largest trial, CASTA, missed its primary endpoint, while the smaller CARS trial reported a benefit and asked for confirmation in a large trial.